Dr. Patrick J. Mille, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Medical University of South Carolina College of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 175
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Medical University of South Carolina College of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
PA license MD448745 -
Hematology (Internal Medicine) Physician
PA license MD448745 -
Internal Medicine Physician
PA license MD448745
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Thomas Jefferson University Hospital Philadelphia, PA
- Jefferson Stratford Hospital Stratford, NJ
- Jefferson Health- Northeast Philadelphia, PA
Medical groups
- Jefferson University Physicians (1,531 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 175
- Services billed
- 574
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 263 | 91 |
| Established patient office or other outpatient visit, 30-39 minutes | 166 | 103 |
| Established patient office or other outpatient visit, 20-29 minutes | 55 | 43 |
| New patient office or other outpatient visit, 60-74 minutes | 29 | 29 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 24 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Philadelphia, PA | 116 |
| Abiraterone Acetate | 106 |
| Nubeqa (darolutamide) | 72 |
| Xtandi (enzalutamide) | 69 |
| Imatinib Mesylate | 41 |
| Dexamethasone Other prescribers in Philadelphia, PA | 24 |
| Eliquis (apixaban) Other prescribers in Philadelphia, PA | 21 |
| Prochlorperazine Maleate Other prescribers in Philadelphia, PA | 18 |
| Amlodipine Besylate Other prescribers in Philadelphia, PA | 18 |
| Ondansetron Hcl Other prescribers in Philadelphia, PA | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $21.31 in total to this clinician.
| Janssen Scientific Affairs, LLC | $21.31 |
|---|
| Food and Beverage | $21.31 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $147,264 in research payments for these studies, mostly to the institutions running them.
- A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Pros…
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.